Skip to Content

Label Changes for:

Zoladex (goserelin acetate) Implant

February 2015

Changes have been made to the WARNINGS and PRECAUTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

February 2015

WARNINGS AND PRECAUTIONS

Injection Site Injury
  • Injection site injury and vascular injury including pain, hematoma, hemorrhage and hemorrhagic shock, requiring blood transfusions and surgical intervention, have been reported with ZOLADEX. Extra care should be taken when administering ZOLADEX to patients with low BMI and/or to patients receiving full dose anticoagulation
     

 

October 2014

5 WARNINGS AND PRECAUTIONS

5.8 Effect on QT/QTc Interval
  • Androgen deprivation therapy may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.

 

June 2013

ADVERSE REACTIONS

Postmarketing Experience
  • Acne: Usually within one month of starting treatment.
  • Other Adverse Reactions: mood swings

 

August 2009 

 

WARNINGS AND PRECAUTIONS

Hyperglycemia

  • Hyperglycemia has been reported in patients receiving GnRH agonists including Zoladex. Hyperglycemia may manifest as diabetes mellitus or worsening of glycemic control. Monitor blood glucose in patients receiving Zoladex and manage with appropriate medical care.

ADVERSE REACTIONS

Pituitary Apoplexy and Tumors
  • Very rare cases of pituitary tumors have been reported.
Glucose Tolerance
  • Reduction in glucose tolerance, manifesting as diabetes or loss of glycemic control in those with preexisting diabetes, has been reported during treatment with GnRH agonists, including Zoladex.
Other Adverse Reactions
  • Psychotic disorders have also been reported.

PATIENT COUNSELING INFORMATION

Males
  • The use of GnRH agonists may cause a reduction in bone mineral density. In men, data suggest the use of a bisphosphonate in combination with an GnRH agonist may reduce bone mineral loss.
  • Patients should be informed that diabetes, or loss of glycemic control in patients with pre-existing diabetes, has been reported during treatment with GnRH agonists, including Zoladex. Consideration should therefore be given to monitoring blood glucose in patients receiving Zoladex.
Females
  • The use of GnRH agonists in women may cause a reduction in bone mineral density. In women, current available data suggest that recovery of bone loss occurs on cessation of therapy in the majority of patients.

 

(web4)